Loading, Please Wait...
NEW YORK, April 19, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Fusion Connect, Inc. (NASDAQ: FSNN) securities between August 14, 2018 and April 2, 2019 (the “Class Period”). Investors have until June 17, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements in various financial statements which were filed with the Securities and Exchange Commission.
On March 13, 2019, Fusion announced that it would postpone its earnings call for the fourth quarter and full year 2018. On April 2, 2019, the company filed a Form 8-K disclosing accounting errors related to an acquisition in 2018, as well as disclosing non-reliance on previously issued financial statements. Fusion also stated that it faced further delay in the filing of its 2018 Form 10-K as a result of accounting errors that required further analysis.
If you purchased Fusion securities during the Class Period or continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Fusion lawsuit, please go to https://bespc.com/fsnn/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.